Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 6998 matches for

- Oxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall - Vaccine 100% effective against severe or critical symptomatic COVID-19 - No safety concerns reported

Oxford coronavirus vaccine researcher Katie Ewer inspects samples in the lab © Photo by John Cairns
Amber Thompson

Amber Thompson

Amber Thompson - Senior QA and Sample Compliance Manager

Rinn Song

Rinn Song

Rinn Song - Clinical Scientist

Emma Francis

Emma Francis

Emma Francis - Research Practitioner

Rebecca Beckley

Rebecca Beckley

Rebecca Beckley - Project Manager

James Gilchrist

James Gilchrist

MBioch, MBBS, MRCPCH, DPhil, PGDip Paediatric Infectious Diseases James Gilchrist - Wellcome Career Development Fellow

Mercy Macharia

Mercy Macharia

Rachel Anslow

Rachel Anslow

Rachel Anslow - Senior Research Assistant

Kai Gao

Kai Gao

Seung Joon Kim

Seung Joon Kim

Pip Crowley

Pip Crowley

Philip Taylor

Philip Taylor

Manon Chatain

Manon Chatain

Manon Chatain - Clinical Research Practitioner

Jo Ning

Jo Ning - Research Assistant

Jesus Caro

Jesus Caro

Jack Howes

Jack Howes

Anna Kelly

Anna Kelly

Hannah Hart

Hannah Hart

Abi Preston-Rees

Abi Preston-Rees

Sir Andrew Pollard

Sir Andrew Pollard

BSc MBBS PhD (Lond), DIC, MRCP (UK), FHEA, FRCPCH, MA, FMedSci, FRS Sir Andrew Pollard - Ashall Professor of Infection & Immunity

Mehreen Adnan

Mehreen Adnan

Load More

Similar stories

New partnership to advance public health and life science research collaboration in West Africa

The Pandemic Sciences Institute, including principal investigators from the Oxford Vaccine Group, has signed a memorandum of understanding with Institut Pasteur de Dakar (IPD) to become a partner institution. PSI and Institut Pasteur de Dakar (IPD) will cooperate on developing vaccines and rapid diagnostics – as well as strengthening workforce in the vaccinology, clinical trials and biomanufacturing sectors.

Trial results for first vaccine against blood-stage malaria show it is well-tolerated and offers effective protection

Ineos Oxford Institute makes award to OVG project tackling antimicrobial resistance

Typhoid vaccine trial confirms sustained protection for older children

Launch of new podcast series Trusting the Science

Oxford scientists launch first-in-human vaccine trial for deadly Marburg virus